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The Gender Medicine Team (GMT), comprised of members with expertise in endocrinology, ethics, genetics, gynecology,
pediatric surgery, psychology, and urology, at Texas Children’s Hospital and Baylor College of Medicine formed a task force to
formulate a consensus statement on practice guidelines for managing disorders of sexual diﬀerentiation (DSD) and for making
sex assignments. The GMT task force reviewed published evidence and incorporated findings from clinical experience. Grading of
Recommendations, Assessment, Development, and Evaluation (GRADE) was used to assess the quality of evidence presented
in the literature for establishing evidence-based guidelines. The task force presents a consensus statement regarding specific
diagnostic and therapeutic issues in the management of individuals who present with DSD. The consensus statement includes
recommendations for (1) laboratory workup, (2) acute management, (3) sex assignment in an ethical framework that includes
education and involvement of the parents, and (4) surgical management.
1. Introduction
A child with a disorder of sexual diﬀerentiation (DSD) poses
a variety of challenges for the treating physician as well as for
the parents and family. Although appropriate management
has long been a matter of concern and often contention,
no clinical practice guidelines have been established to
help physicians inform parents and implement management
approaches in a standardized fashion [1–8]. Our aim was
to develop practice guidelines for managing DSD and for
making sex assignments. Accordingly, we formed a Gender
Medicine Team (GMT) task force, comprised of experts in
the fields of endocrinology, ethics, genetics, gynecology, psy-
chology, and urology, to evaluate the information available
from our own experience and from a review of the literature.
We utilized the Grading of Recommendation, Assessment,
Development, and Evaluation (GRADE) system to grade
the evidence and recommendations. With the review and
recommendations oﬀered by our task force, we developed a
consensus statement for clinical management of DSD and for
making sex assignments.
2. Methods
The GMT task force first identified four clinically relevant
questions to be answered from the evidence. These questions
were the following.
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Question 1. What constituted the most appropriate evalu-
ation for infants with ambiguous genitalia or a DSD? This
question was divided into the following subquestions.
(1a) What is the appropriate evaluation for CAH?
(1b) What is the most appropriate way to assess the hypotha-
lamic pituitary gonadal axis in the context of ambigu-
ous genitalia or hypothalamic pituitary hypogonadism?
(1c) What is the most appropriate evaluation for micropenis
and for undescended testes for the evaluation of
primary hypogonadism most likely in the context of
dysgenetic testes?
(1d) What is the most appropriate evaluation for peripheral
defects leading to micropenis, hypospadias with respect
to [1, 2] the action of testosterone which could be in
the context of (a) 5 alpha-reductase deficiency or (b)
biochemical and molecular genetic testing for androgen
receptor defect, and [3] the production of testosterone
with respect to the enzymatic machinery,
(1e) What genetic testing should be performed for
ambiguous genitalia?
Question 2. What is the most appropriate management for
infants with ambiguous genitalia or a DSD who present with
a life-threatening complication as a result of their condition?
Question 3. What is the most appropriate approach to sex
assignment in an infant with ambiguous genitalia or a DSD?
This question was divided into the following subquestions.
(3a) Should clinical decision making for DSD be physician-
dependent or reside within a Gender Medicine Team?
(3b) What role should the psychologist play on the Gender
Medicine Team?
(3c) What is the ethical framework for sex assignment?
Question 4. What is the most appropriate surgical manage-
ment for infants with ambiguous genitalia or DSD? This
question was divided into the following subquestions.
(4a) What is the most appropriate surgical management for
infants with CAH?
(4b) What is the most appropriate feminizing surgery
management of patients with DSD?
(4c) What is the most appropriate masculinizing surgery
management of patients with DSD?
(4d) What is the most appropriate gonadectomy surgery
management of patients with DSD?
The GMT task force then searched databases for
research-based articles on infants/children with ambiguous
genitalia or DSD. Databases included Cochrane Collabora-
tion, PubMed, and Google Scholar. Articles were restricted to
English-based publications. Key words/terms used to search
the databases included: acute management, ambiguous gen-
italia, anatomical sex, androgen synthesis, chromosomal sex,
gonads, hormonal sex, medical emergency, molecular sex,
phallic structure, pigmentation of the genitalia, reproductive
sex, sex assignment, sex of rearing, and “46,XX”male infants.
In addition, surgical terms included vaginoplasty, clitoral
reduction, clitoroplasty, and masculinizing and feminizing
surgery.
Searches of the literature were performed for each topic
and graded by a member of the Texas Children’s Hospital
Evidence-Based Outcomes Center using the approach rec-
ommended by the Grading of Recommendations, Assess-
ment, Development, and Evaluation (GRADE) group [9,
10]. The GMT task force “used the best available research
evidence that members identified to inform the recom-
mendations and consistent language” of “both the strength
of a recommendation and the quality of evidence” [10].
The quality of the evidence was evaluated as “very low
quality,” “low quality,” “moderate quality,” or “high quality.”
Recommendations were denoted as “strong” or “weak.”
In conjunction with the GRADE system, the GMT
task force evaluated an approach in practice by the Texas
Children’s Hospital Evidence-Based Outcomes Center. To
formulate the consensus statement, members of the task
force systematically reviewed the data according to their areas
of expertise and contributed to the statement accordingly.
Questions were distributed before drafting a manuscript and
reaching a final consensus. Each member of the task force
approved the final materials used. The final manuscript and
the consensus statement were approved based on a vote by all
members of the task force.
3. Results
The review of the literature using the Cochrane Collabora-
tion, PubMed, SCOPUS, andGoogle Scholar yielded the arti-
cles for most of the questions posed. We found that a paucity
of articles exists for this topic as a coherent whole but that
almost all the questions were addressed in the literature, if
only by one or a few articles. The results are provided below.
Question 1. What constituted the most appropriate evalu-
ation for infants with ambiguous genitalia or a DSD? We
found that few outcome studies address the appropriate
workup for children with DSD. A review of the literature
called for using a multidisciplinary team and various diag-
nostic procedures for performing the workup. Literature
results for the specific questions identified in order to arrive
at a final consensus were the following.
(1a) What is the appropriate evaluation for CAH? Three
articles were specifically relevant to our research. One was
a review article by Sultan et al. [11]. The other two articles
that were useful were a review by Speiser and White [12],
specifically addressing CAH and the consensus statement of
the Lawson Wilkins Pediatric Endocrine Society and The
European Society for Paediatric Endocrinology [13].
(1b)What is the most appropriate way to assess the hypothala-
mic pituitary gonadal axis in the context of ambiguous genitalia
or hypothalamic pituitary hypogonadism? In addition to the
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Patient with DSD 
Rule out medical emergency in the context of hypopituitarism or CAH 
Order the appropriate work-up as per phenotype and clinical assessment
(electrolytes, glucose, hormonal studies, chromosome analysis, stimulation test)
Start the process of sex assignment by involving the team 
Meet the family: psychologist to evaluate their perceptions for sex assignment 
Multidisciplinary evaluation of the case 
Sex assignment decision process 
Process of sex assignment 
Delay surgery until all the information available 
Assess the medical and ethical aspects of surgical interventions
Figure 1
article by Sultan et al. [11] noted above, two review articles
were pertinent: one by Grumbach [14] and the other a
retrospective article by Parisi, et al. [15].
(1c) What is the most appropriate evaluation for micropenis
and for undescended testes for the evaluation of
primary hypogonadism most likely in the context of
dysgenetic testes? Two retrospective studies, one by
Kolon and Miller [16] and one by Davenport, et al.
[17], and an observation study by Mirsa, et al. [18]
specifically address our purposes.
(1d) What is the most appropriate evaluation for peripheral
defects leading to micropenis, hypospadias as related
to [1, 2] the action of testosterone which could be in
the context of (a) 5 alpha-reductase deficiency or (b)
biochemical and molecular genetic testing for androgen
receptor defect and [3] the production of testosterone
with respect to the enzymatic machinery.
With respect to [1, 2] the action of testosterone, in the context
of
(a) 5 alpha-reductase deficiency in addition to relying on
the ordinary established practice of ordering testos-
terone and dihydrotestosterone, we found useful a
retrospective observational study by Boehmer et al.
[19, 20] and case reports by Imperato-McGinley et
al. [21] and Cai et al. [22].
(b) The molecular genetic testing for the androgen receptor,
We found a case study by Deeb et al. [23].
With regard to [3] the production of testosterone with
respect to the enzymatic machinery, our search of the literature
yielded two observational studies, one by Codner et al. [24]
and one by Eckstein et al. [25].
(1e) What genetic testing should be performed for ambiguous
genitalia? Our search of the literature yielded the review
article by Parisi et al. [15] and a retrospective observational
study by Lu et al. [26].
Question 2. What is the most appropriate management for
infants with ambiguous genitalia or a DSD who present with
a life-threatening complication as a result of their condition?
A review of the literature revealed no studies specifically
evaluating the emergency management of children with
ambiguous genitalia or DSD. We used the review articles by
Sultan et al. [11] and Speiser and White [12].
Question 3. What is the most appropriate approach to sex
assignment in an infant with ambiguous genitalia or a DSD?
The literature search yielded the following articles that
addressed the subquestions we posed in order to derive a final
consensus.
(3a) Should clinical decision making for DSD be physician-
dependent or reside within a Gender Medicine Team?
(Figure 1). Two articles were useful in our attempt to answer
this question: an evidence-based model by Schaeﬀer, et al.
[27] and a study by Axelrad et al. [28].
(3b) What role should the psychologist play on the Gender
Medicine Team? The review article by Parisi et al. [15]
includes the use of a psychiatrist. The literature also yielded
observational studies by Reiner and Gearhart [29], Migeon
an Wisniewski [30], and Wisniewski et al. [31], as well as a
review article in the American Academy of Pediatrics Section
on Urology [32].
(3c) What is the ethical framework for sex assignment?
We used a published critical appraisal tool to assess the
literature on the ethics of DSD [33]. We also identified two
proposed ethical frameworks for the management of DSD,
by McCullough [34, 35] and by Wiesemann et al. [36], and a
statement from an interdisciplinary research group from The
Hastings Center by Frader et al. [37].
Question 4. What is the most appropriate surgical manage-
ment for infants with ambiguous genitalia or DSD?
To answer this question, we searched the literature for
information addressing the following subquestions.
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(4a) What is the most appropriate surgical management
for infants with CAH? The search yielded several useful
articles: a retrospective observational study conducted by
Stikkelbroeck et al. [38] and studies by Nordenskjo¨ld et al.
[39] and Schnitzer and Donahoe [40]. The evidence-based
model by Schaeﬀer et al. [27] also provides details on the
surgical management of CAH.
(4b) What is the most appropriate feminizing surgery man-
agement of patients with DSD? The literature search yielded
a total of 45 relevant English-written articles, 18 of which
specifically addressed disorders resulting in 46, XX DSD and
16 of which addressed disorders resulting in vaginal agenesis,
such as complete androgen insensitivity, Meyer Rokitansky
Kuster Hauser syndrome, or CAH with urogenital sinus. All
articles identified by the initial search criteria were scanned
for significance by reviewing the title and abstract content.
Additional articles were excluded if they were written in
a language other than English, had no relevance to the
question of interest, if they were case reports, review articles
on the topic, expert opinions, or letters to the editor.
Literature appraisal criteria determined the study quality
and bias. Evaluation of available literature was based on
GRADE criteria from weak recommendation with very
low-quality evidence to strong recommendation with high-
quality evidence. After GRADE criteria were applied, only 19
papers met standards for this intensive review to determine
specific study characteristics such as age when surgery
performed, need for reoperation or revision, Prader grading,
and pubertal status.
(4c) What is the most appropriate masculinizing surgery
management of patients with DSD? Total retrieval was 34
English and 6 non-English references. After initial abstract
review, 13 articles were excluded because they did not address
the questions of interest, or they were not applicable to
our patient population. Ten articles were excluded because
they were reviews or consensus statements. Six others were
excluded because they were written in a foreign language.
Thus, a total of 11 full articles in English were retrieved after
abstract review. These studies were deemed to be eligible
based on their potential to address the topics of interest.
The GRADE criteria were applied to each study to evaluate
its methodological quality. After analysis of all 11 articles
for methodological rigor and relevance, we determined that
there was a profound deficit of high-quality evidence to
substantiate our recommendations. Therefore, we opted
to accept all 11 manuscripts, despite their lesser quality
and relative weaknesses and flaws, to be included in our
assessment and to help guide our recommendations in this
paper. Our review of the literature yielded low-quality data
to support a single, unified surgical approach to patients
with 46, XY DSD. The articles that were useful included a
retrospective study by Chertin et al. [41], reports by Go¨llu¨ et
al. [42] and Lam et al. [43], a retrospective review by Nihoul-
Feke`te` et al. [44], and a long-term follow-up study by Farkas
et al. [45], as well as reports by Mendonca et al. [46] and
Lima et al. [47]. With regard to the appropriate timing of
surgical intervention for patients with ovotesticular DSD and
an underandrogenized perineum, no conclusive high-quality
evidence was found.
(4d) What is the most appropriate gonadectomy surgery
management of patients with DSD? There are limited
prospective studies available regarding gonadectomy for
children and adolescents with disorders of sexual diﬀerentia-
tion. Retrospective analyses and review articles were utilized
using the following search terms: gonadectomy, malignant
transformations, seminoma, and dysgenetic gonads. The
articles we used were a case study by Olsen et al. [48] and
reports by Dumic et al. [49] and Fallat and Donahoe [50].
4. Discussion
To evaluate and grade the evidence, we used the grading
system developed by the GRADE, an international group
with expertise in the development and implementation of
evidence-based guidelines [9]. The GRADE system we used
has been adopted by The Endocrine Society and a growing
number of other organizations to develop clinical practice
guidelines and to grade the strength of recommendations
and the quality of the evidence [10, 51]. Linked to each
recommendation is a description of the evidence, values
that panelists considered in making the recommendation
(when making these explicit was necessary), and remarks,
a section in which panelists oﬀer technical suggestions for
testing conditions, dosing, and monitoring. These technical
comments reflect the best available evidence applied to a
typical patient. Often, this evidence comes from the unsys-
tematic observations of the panelists and should, therefore,
be considered “suggestions.” A detailed description of this
grading scheme has been published elsewhere [10].
The GMT task force has confidence that patients who
receive care according to the strong recommendations will
derive, on average, more good than harm. Strong recommen-
dations require more careful consideration of the patient’s
circumstances, values, and preferences to determine the best
course of action.
Based on this system, we developed our guidelines for
each question identified in the Methods and Results sections,
as noted below.
Question 1. What constituted the most appropriate evalu-
ation for infants with ambiguous genitalia or a DSD? The
guideline for this question was developed after we reviewed
and graded the literature for the following subquestions.
(1a)What is the appropriate evaluation for CAH? The review
article by Sultan et al. [11] recommends using a multidisci-
plinary team in every step of the diagnostic procedure, sex
assignment, and treatment strategy. The authors suggest that
the diagnostic workup should include family history, general
examination for dysmorphic features, and grading based on
the presence or absence of gonads and their palpability:
(a) no gonads palpable (46, XX DSD, congenital adrenal
hyperplasia [21-hydroxylase deficiency] or 46, XY DSD); (b)
one gonad palpable, or abnormal gonadal diﬀerentiation (46,
International Journal of Pediatric Endocrinology 5
XY DSD, mixed gonadal dysgenesis [XO/XY], ovotesticular
DSD); (c) two gonads palpable, or 46, XY DSD, impaired
testosterone biosynthesis (androgen receptor defect 5c-
reductase deficiency, ovotesticular DSD). This approach is
relevant tomore than just CAH. Approximately 75 percent of
patients who present in the emergency roomwith ambiguous
genitalia with hyponatremia and hyperkalemia and a lack of
palpable testes have a diagnosis consistent with CAH.
Speiser and White [12] report that progress has been
made with regard to the genetics of the various clinical
forms of 21-hydroxylase deficiency, that the correlations
between the genotype and the phenotype have been studied
extensively, and that gene-specific prenatal diagnosis is now
feasible. A consensus statement of the Joint LWPES/ESPE
CAH Working Group [13] is in agreement with the state-
ments made in the report by Speiser and White.
The newborn screen for CAH also might contribute
insights in the diagnosis of a newborn in the setting of
ambiguous genitalia with nonpalpable testes. However, the
results of the newborn screen might not always precede the
presentation [13].
There are no outcome studies addressing the above
question.
Recommendation. We recommend that the standard workup
for CAH include the following: electrolytes, glucose, 17OHP,
plasma renin, D4 androstenedione, testosterone, 11deoxy-
cortisol, and DHEA. (weak recommendation, very low-
quality evidence).
(1b)What is the most appropriate way to assess the hypothala-
mic pituitary gonadal axis in the context of ambiguous genitalia
or hypothalamic pituitary hypogonadism? The underlying
problemmost likely is a hypothalamic GnRH pulse generator
defect with subsequent hypogonadotropic hypogonadism.
This condition might be in isolation or in the context
of hypopituitarism. However, to establish the diagnosis
of isolated hypogonadism in the context of micropenis,
hypopituitarism needs to be ruled out. The GNRH pulse
generator has developed and is well functional by the end of
first trimester.
The article by Sultan et al. [11], who recommend the use
of a multidisciplinary team in every step of the diagnostic
procedure, sex assignment, and treatment strategy, was
useful in this context as well as for addressing question (1a).
Grumbach [14] noted that because levels of FSH, LH,
and sex steroid secretion are low in childhood and male
infant levels of testosterone increase during the second week,
reaching a maximum at 4 to 10 weeks and declining to low
levels by the time the child is approximately 6 months old, in
the scenario of micropenis with or without cryptorchidism,
it is imperative to exploit the window of opportunity in order
to establish the diagnosis hypogonadotropic hypogonadism.
If the infantile GnRH gonadotropin spurt is captured,
hypogonadotropic hypogonadism would be identified by the
blunt response or ruled out by the appropriate peak. Estab-
lishing the diagnosis of hypogonadotropic hypogonadism in
infancy precludes the uncertainties and delays in distinguish-
ing constitutional delay in puberty from hypogonadotropic
hypogonadism. Accordingly, hormone replacement therapy
can be initiated at the normal age of pubertal onset. Infants
with micropenis should be administered testosterone.
Parisi et al. [15] describe a Gender Assessment Team that
has provided a multidisciplinary approach to the diagnosis,
medical and surgical treatment, genetic counseling, and
psychosocial support of 250 patients with DSD. These
authors recommend that the endocrine evaluation include
an assessment of the function of the hypothalamic pituitary
gonadal axis and that studies include a gonadotropin profile,
assessment of gonadal function, and assessment of other
pituitary axes when indicated. The article states that tests are
most revealing when obtained in infants between 2 and 4
months old.
There are no outcome studies addressing the above
question.
Recommendation. We recommend the use of a multidisci-
plinary team for the assessment of the hypothalamic pitu-
itary gonadal axis, that the diagnosis of hypogonadotropic
hypogonadism should be established within the first 6
months of life, and that appropriate hormonal replacement
therapy should be initiated immediately. (Strong recommen-
dation, very low-quality evidence).
(1c) What is the most appropriate evaluation for micropenis
and for undescended testes for the evaluation of primary hypog-
onadism most likely in the context of dysgenetic testes? In
the context of primary hypogonadism, dysgenetic testes need
to be ruled out. In their retrospective observational study,
Kolon et al. [16] evaluated 77 prepubertal boys diagnosed
with hypospadias, cryptorchidism, or micropenis. Sixty boys
underwent one dose of human chorionic gonadotropin
(hCG), and 17 underwent three daily age-adjusted doses of
hCG. In the one-dose group, poststimulation testosterone
was elevated 22- to 29-fold from baseline after a weight-
based dose was administered and 34- to 35-fold after a dose
based on body surface area was given. Testosterone increased
20-fold baseline in the multidose group. No significant
diﬀerence was noted between the dihydrotestosterone levels
in the single weight-based dose and the three-injection
regimen.
In a retrospective observational study, Davenport et al.
[17] reviewed the value of the hCG test in the evaluation
of prepubertal boys with bilateral impalpable testes. The
study was comprised of 31 boys, all of whom had an hCG
test consisting of three intramuscular injections of hCG on
successive days at a daily dose dependent on their age (<1
year old, 500 units; 1–10 years, 1000 units; >10 years, 1500
units). Twenty-two boys responded to hCG and had testes
the sizes of which were related to the degree of testosterone
elevation after the stimulatory test. hCG had a positive
predictive value of 89 percent and a negative predictive value
of 100 percent. Measurements of gonadotropins and sex
hormones can be substituted occasionally instead of hCG, in
a narrow window when the infant is 14 days old to 90 days
old [14].
The observational study conducted by Misra et al.
[18] examined the role of Mullerian inhibiting substance
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(MIS) determination in the evaluation of 218 boys with
mircorphallus and/or cryptorchidism. MIS was normal in
69.2 percent of boys with isolated microphallus compared
with 38.1 percent of boys with microphallus and coexisting
cryptorchidism (P < .05).
Recommendation. We recommend using hCG stimulation
for the evaluation of primary hypogonadism and obtaining
basal MIS measurement. (Strong recommendation, low-
quality evidence).
(1d) What is the most appropriate evaluation for peripheral
defects leading micropenis, hypospadias, with respect to .
(1) the action of testosterone, which could be in the context
of
(a) 5 alpha-reductase deficiency.
In a retrospective observational study, Boehmer et al. [19, 20]
reviewed 49 cases with presumptive diagnosis of androgen
insensitivity syndrome. The review found that in 32 of the 49
(65.3%) patients, an androgen receptor gene mutation was
found.
A case report on a 65-year-old male with 5 alpha-
reductase deficiency 46, XY DSD was described by Imperato-
McGinley et al. [21]. The man had no medical intervention
before, during, or after puberty. The authors discovered that
plasma levels of dihydrotestosterone and the in vivo conver-
sion of radiolabeled testosterone to dihydrotestosterone were
decreased.
In addition, an original pertinent case study by Cai
et al. [22] of four Dominican families based on a study
published in 1974 describes a large Dominican kindred of 23
families with 38 aﬀected subjects, pointing to the autosomal
recessive nature of the disease. Characterization of 5 alpha-
reductase enzyme activity in cultured genital skin fibroblasts
demonstrated a pattern of enzyme activity distinctly diﬀerent
from three previously described families with this condition.
Single-strand polymorphism and DNA sequencing were
used. Two other mutations of the 5 alpha-reductase-2 gene
were found in aﬀected subjects from two of the four families.
One of these families had a point mutation on exon 2
of the 5 alpha-reductase-2 gene, in which substitution of
adenine (GAC) for guanine (GGC) caused an aspartic acid
replacement of glycine at amino acid 115 (G115D), and the
other family had a substitution of adenine (AGT) for guanine
(GGT) on exon 3, causing a serine replacement for glycine
at amino acid 183 (G183S). Aﬀected subjects from the two
remaining families demonstrated the same exon 5 mutation
of the 5 alpha-reductase-2 gene as previously detected in the
large Dominican kindred. The phenotypic and biochemical
characteristics of the 46, XY DSD were similar regardless of
the genetic defect, except that one aﬀected subject (C-VI-
2) with the same exon 5 mutation as the large Dominican
kindred had much more facial and body hair.
(b) biochemical and molecular genetic testing for androgen
receptor defect
Deeb et al. [23] report a patient with severe under-
masculinization and poor response to exogenous andro-
gens. Androgen binding was performed, the AR gene was
sequenced, and functional studies of themutant protein were
performed. The authors found that androgen binding was
normal and that the novel mutation (A629W) in the AR
hinge region resulted in severe undermasculinization at birth
and resistance to androgens.
The McGill Androgen Receptor Gene Mutations
Database [52] holds a collection of such characterized
mutations in the AR gene, providing a valuable tool of
genotype-phenotype correlation.
Although the diagnostic tools of testosterone dihy-
drotestosterone and their ratios either in minipuberty or
under hCG are applied for confirmation of the diagnosis
or for genetic counseling, it is necessary to proceed with
the molecular diagnosis. Likewise, although it has been
reported that MIS levels are helpful for indirect evaluation of
androgen receptor defects, this observation is based on only
a few reports [53].
Recommendation. We recommend (1) screening the andro-
gen receptor gene for mutations, (2) studying androgen
receptor expression and androgen binding in genital skin
fibroblasts, and (3) evaluating testosterone levels. (Strong
recommendation, very low-quality evidence).
(2) the production of testosterone with respect to the
enzymatic machinery?
Codner, et al. [24] conducted an observational study to
determine whether some patients with idiopathic hypospa-
dias have HSD3B2 mutations. They measured basal plasma
renin activity and performed an ACTH test for determina-
tion of 17-OH-pregnenolone, 17-OH-progesterone, cortisol,
dehydroepiandrosterone sulfate, and androstenedione, and
they used a human chorionic gonadotropin test for the
determination of androstenedione, testosterone, and dihy-
drotestosterone on 90 patients with penile or perineoscrotal
hypospadias and 101 healthy fertile male controls. They did
not observe a clear steroidogenic pattern suggestive of 3 beta-
HSD deficiency in any patient.
Eckstein et al. [25] conducted an observational study in
six Arab individuals with familial 46, XY DSD caused by
17-beta hydroxysteroid dehydrogenase deficiency. The study
revealed several metabolic aberrations associated with the
disorder. The study also found that plasma androstenedione
concentrations increased with age (29 ng/dL at 3 years of
age to 563 ng/dL at 26 years of age) and that hCG markedly
increased the plasma androstenedione in all six patients.
Recommendation. We recommend administering hCG to
patients in order to increase androstenedione secretion,
allowing for the diagnosis of the defect in prepubertal indi-
viduals. (Strong recommendation, low-quality evidence).
Widely available androgen receptor gene molecular
testing is available allowing the detection of hundreds of
clinically recognized mutations and further confirmation
of the clinical diagnosis of complete and partial androgen
insensitivity.
Recommendation. We recommend screening the androgen
receptor gene for mutations, in cases of suspected complete
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or partial androgen insensitivity. (Strong recommendation,
low-quality evidence).
Clinical molecular testing is now available for the
evaluation of the 5 alpha-reductase-2 gene, building on
knowledge gained from clinical cases, as outlined above,
and correlation with mutations identified on both research
and clinical bases. As with defects in the androgen receptor
gene, although measuring testosterone, dihidrotestosterone,
and their ratios either in minipuberty or under hCG
can be helpful, confirmation of aﬀected status suspected
biochemically can now be diagnosed by molecular genetics.
Recommendation. We recommend molecular testing for 5
alpha-reductase-2 gene mutations when suspected based
on phenotypic and biochemical characteristics. Overall, the
GMT task force recommends the use of various diagnostic
procedures and a multidisciplinary team approach for the
workup of infants with ambiguous genital or a DSD. (Strong
recommendation, very low-quality evidence).
(1e) What genetic testing should be performed for ambiguous
genitalia? Parisi et al. [15] recommend karyotype analysis
on peripheral blood or skin fibroblasts derived from genital
skin or other sources, fluorescence in situ hybridization
(FISH) to augment routine cytogenetics for rapid analysis
and evaluation for sex chromosome mosaicism and/or
chimerism, FISH for presence or absence of the sex-
determining region on the Y chromosome (SRY), specialized
molecular genetic testing for Y chromosome deletions, and
other additional specialized genetic tests if indicated, based
on the specific condition being evaluated.
The genetic field also has seen the emergence of array
comparative genomic hybridization (aCGH), which is prov-
ing very useful in the evaluation of cases of ambiguous geni-
talia by simultaneously being able to provide the same infor-
mation as a standard karyotype, evaluate for sex chromo-
some mosaicism and/or chimerism, and detect the presence
or absence of SRY. This technology also has the advantage
of being able to detect copy number abnormalities in the
rest of the genome, which have traditionally been below the
resolution of a standard karyotype. A growing number of
such regions are being associated with ambiguous genitalia.
A retrospective observational study by Lu et al. [26]
evaluated 638 neonates with various birth defects who
were referred for chromosomal microarray analysis. Twelve
patients presented with ambiguous genitalia. Targeted array-
based comparative genomic hybridization had an overall
detection rate of 33.3 percent in patients with ambiguous
genitalia. This methodology can expedite and simplify the
evaluation for ambiguous genitalia by identifying genomic
imbalances and in some cases even mosaic abnormalities
precisely and rapidly, providing timely molecular diagnoses,
detecting more clinically relevant genomic abnormalities
than can conventional cytogenetic studies, and supporting
more informed decision making and management.
Recommendation. We recommend obtaining a karyotype
and including additional testing as appropriate based on the
phenotype and karyotype of the patient. We also recommend
including array CGH testing as a part of the genetic workup
for DSD. (Strong recommendation, low-quality evidence).
Question 2. What is the most appropriate management for
infants with ambiguous genitalia or a DSD who present with
a life-threatening complication as a result of their condition?
The review article by Speiser and White [12] describes
the workup required in cases of emergencies. These authors
recommend that for CAH (and they include hypopituitarism
with modifications), management should be directed toward
the emergency condition: (a) for cases of suspected CAH
(salt-losing variety), the physician should order a laboratory
workup; the infant should be treated with D5 NS (dextrose
in normal saline) and stress steroids (100mg/m 2/day),
with treatment modified after 24 hours, based on electrolyte
correction; Florinef (0.1mg po qd) should be added, with a
switch to table salt (2.5 grams po qd/given in 24-hr worth
of formula); (b) for cases of micropenis, and suspicion of
hypopituitarism (the concern is hypoglycemia), the pituitary
adrenal axis should be assessed for production of cortisol;
the physician should initiate treatment (stress steroids:
100mg/m 2/day Solucortef) while laboratory results are
pending; (c) if neither of the acute conditions is the final
diagnosis, the physician should withhold treatment until
after the results of the workup are available.
Sultan et al. [11] recommendedmanagement of the acute
presentation of suspected CAH with Solucortef stress doses
and management of the chronic condition with glucocorti-
coids (hydrocortisone 10 to 20mg/m2/day:tid Mineralocor-
ticoids: 0.1 to 0.2mg of Fludrocortisone sodium chloride 1
to 2.5 grams or 17 to 42mmol of sodium chloride daily).
There are no outcome studies addressing the above
question.
Recommendation. We recommend that treatment with stress
dose steroids be initiated immediately, pending laboratory
results. (Weak recommendation, very low-quality evidence).
Question 3. What is the most appropriate approach to sex
assignment in an infant with ambiguous genitalia or a DSD?
The guideline for this question was developed after
we reviewed and graded the literature for the following
subquestions.
(3a) Should clinical decision-making for DSD be physician-
dependent or reside within a Gender Medicine Team? Prac-
tical guidelines have not been established for this situation
as there are few outcome studies, and decision-making
criteria have not been formally developed. Accordingly, we
incorporated systematic reviews of the literature, which have
guided and formulated our consensus practice at Texas
Children’s Hospital (TCH).
A review article by Schaeﬀer et al. [27] interprets and
translates the 2002 consensus statement [13] noted earlier
into medical, surgical, and mental health protocols and
provides preliminary evidence that such protocols result in
improved care and support for patients and families.
In an article by Axelrad et al. [28], the multidisciplinary
Gender Medicine Team approach used at TCH is described
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and is recommended over the traditional physician-
determined approach. The TCH approach includes (a) an
ethical framework involving a team of specialists (including
an ethicist) and (b) education and participation of the
parents in the decision-making process. It is more compre-
hensive than other approaches previously reported and is
designed to meet the multifaceted needs of individuals with
DSD.
There are no outcome studies addressing the above
question.
Recommendation. We recommend the use of a consensus
approach that includes an ethical framework for parental
decision-making, rather than the traditional physician-
determined approach, when determining sex assignment
in an infant with ambiguous genitalia or a DSD. (Strong
recommendation, very low-quality evidence).
(3b) What role should the psychologist play on the Gen-
der Medicine Team? Specific guidelines have not been
established for this component as there are few outcome
studies, and decision-making criteria have not been for-
mally developed. Our clinical experience and the literature
have shown that during diagnosis, medical workup, acute
management, sex assignment, and throughout treatment,
parents and aﬀected children often have diﬃculties coping,
have questions about how to manage inquiries from family
and friends, experience uncertainty about the future, and
at times demonstrate significant symptoms of anxiety and
depression. The main task of the psychologist is to assist in
the education and involvement of the parents to the best
of the ability of the family members and to assess whether
psychosocial diﬃculties are impacting the understanding of
guidelines by any family members. The psychologist assists
the family members in coping with the presentation of a
medical diﬃculty in their child as well as normalizing the
taboo often associated with the particular diagnoses involved
[28].
Parisi et al. [15] include a psychologist in the recom-
mendation for a team approach. An observational study by
Reiner and Gearhart [29] assessed 16 genetic males in a
cloacal-exstrophy clinic at the ages of 5 to 16 years. Eight of
the 14 subjects assigned to female sex declared themselves
male during the course of the study whereas the two
children reared asmale remainedmale. Sexual identity varied
among the subjects assigned the female sex. Five persistently
declared unwavering female identity, one refused to discuss
sexual identity, and eight declared unwavering male identity.
All subjects living as females expressed diﬃculty fitting in
with female peers. The study revealed that neonatal sex
assignment can result in unpredictable sexual identification
and can present a variety of issues related to a child’s
psychosexual development.
In their observational study, Migeon et al. [30] inter-
viewed 75 adults with 45, XY karyotype who presented
as infants or children with variable degrees of undermas-
culinization of their genitalia treated at the Johns Hopkins
Hospital Endocrine Clinic. Participants’ knowledge of their
condition, satisfaction with their knowledge, and desire for
additional education about their intersex conditions were
assessed. Almost half of the patients, reared male or female,
were neither well-informed about their medical and surgical
history nor satisfied with their knowledge.
The observational study by Wisniewski [31] assessed by
questionnaire and medical exam 14 women with complete
androgen insensitivity syndrome (CAIS). Eleven of the 14
(78%) women reported satisfaction with their genitalia; eight
of the 14 (57%) women reported being mainly satisfied
with their bodies; and five of the 14 (36%) reported being
somewhat dissatisfied. All 14 women were satisfied with their
sex of rearing, and 93 percent of women reported being
heterosexual. The majority of women with CAIS studied
received some form of counseling (83%) at various ages
and for various lengths of time concerning aspects of their
syndrome.
The review article in the American Academy of Pediatrics
Section on Urology [32] considers the psychological factors
associated with elective surgery on the genitalia of male
children with hypospadias. The article noted that emotional,
cognitive, and body-image developmentmay be aﬀected pro-
foundly by both the genital deformity and the reconstructive
surgery, and that aesthetic trauma varies dramatically by
age. Postoperative behavioral problems such as aggressive or
regressive behavior, night terrors, and anxiety may be more
common at certain ages.
The description of the team approach by Axelrad et al.
[28] includes a psychologist for various stages of the process
and for family members.
Recommendation. We recommend the presence of a psychol-
ogist on the Gender Medicine Team to provide support to
both patients and caregivers. (Strong recommendation, low-
quality evidence).
(3c) What is the ethical framework of sex assignment? We
used a published critical appraisal tool to assess the literature
on the ethics of DSD: “Argument-based medical ethics: a
formal tool for critically appraising the normative medical
ethics literature” [33]. We identified two proposed ethical
frameworks for the management of DSD, by McCullough
[34, 35] and by Wiesemann et al. [36] in “Ethical principles
and recommendations for the medical management of
diﬀerences of sex development (DSD)/intersex in children
and adolescents”, and a statement from an interdisciplinary
research group from The Hastings Center by Frader et al.
[37]. The ethical frameworks and the statement emphasize
the need to base ethical judgments on an evidence-based
assessment of the aﬀected infant; the centrality of the best
interests of the infant and child it will become; the obli-
gation of healthcare professionals to involve parents in the
decision-making process; the obligation to avoid irreversible
interventions and to undertake them only when they can
be rigorously justified as necessary to protect and promote
the interests of the infant and child it will become; the need
to involve children in decision making appropriate to their
developmental stages; the obligation to take into account the
biopsychosocial variation in sex, gender, and gender identity
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and also cultural changes in which rigid gender identities and
roles are being challenged by gender ambiguity.
The tools of ethics are (a) analysis of concepts to ensure
that their meaning is clear and (b) argument, the use
of logical reasoning to identify the implications of ethical
concepts. These implications should then guide clinical
judgment, decision making, and management. Rigorous use
of concepts to make arguments produces conclusions that
can be relied up to guide clinical practice.
The ethics of using clinical guidelines is based on the
concept of fiduciary responsibility for the patient. This
ethical concept was introduced into the history of medical
ethics by two British physician-ethicists in the eighteenth
century, John Gregory (1724–1773) of Scotland and Thomas
Percival (1740–1804) of England.
Fiduciary responsibility has three components. (1) Physi-
cians and other healthcare professionals should become sci-
entifically and clinically competent by adhering to the rigors
of the scientific method, as articulated in Francis Bacon’s
(1561–1626) “experience”-based philosophy of medicine.
This was a nascent form of what has become evidence-
based reasoning. The goal is to submit clinical judgment
and decision making to the discipline of experience-based
(evidence-based) practice to reduce bias in, and thereby
increase the scientific reliability of, clinical judgment and
decision making and thus create the intellectual integrity
of the profession of medicine. (2) Physicians and other
healthcare professionals should make the protection and
promotion of the patient’s health-related interests their
primary concern and motivation. (3) Physicians and other
healthcare professionals should treat medicine, psychology,
nursing, and the other healthcare professions as public trusts
that exist for the benefit of future physicians, patients, and
society [33].
Practice guidelines are an essential tool for implementing
the first component routinely in clinical practice. This
consideration is especially important in the responsible
management of DSD in light of the history of wide variation
in clinical judgment and practice, resulting inmany unneces-
sary and irreversible surgical interventions that have not been
uniformly clinically beneficial and often clinically harmful.
Responsible management of DSD is guided by two
ethical considerations. The first is to take account of the
variations in the diﬀerent components of biological sex,
including genomic sex, anatomic sex (internal and external),
hormonal sex, and brain sex and to appreciate that the
more discordant these components of biological sex, the
more variation that will be observed in subsequent gender,
including gender identity and sexual orientation. When
the components of biological sex align strongly, reliable
predictions of gender identity can be made and recom-
mendations for sex assignment can be made accordingly.
The second ethical consideration is to prevent irreversible
anatomic and physiologic eﬀects of surgical assignment of
sex, an especially compelling ethical consideration when the
components of biological sex do not strongly align. The
goal in such cases should be to preserve the anatomic and
physiologic components of a change in gender identity later
in a child’s life [34].
There are no outcome studies addressing the above
question.
Recommendation. We recommend that an ethicist be con-
sulted on each case to ensure that the patient’s individual
needs are addressed according to the ethical framework
established by the GMT. (Strong recommendation, very low-
quality evidence).
Question 4. What is the most appropriate surgical manage-
ment for infants with ambiguous genitalia or DSD?
The guideline for this question was developed after
we reviewed and graded the literature for the following
subquestions.
(4a) What is the most appropriate surgical management for
infants with CAH? The retrospective observational study
conducted by Stikkelbroeck et al. [38] evaluated eight female
patients with salt-wasting CAH who underwent feminizing
surgery in infancy from 1973 to 1983. The study consisted
of a review of the patients’ medical records (n = 8), a
systematic evaluation of the current situation (n = 6) that
included a written questionnaire to screen for psychopathol-
ogy (YASAR), a structured gynecological examination, and
a psychosexual interview. The patients were matched to 19
healthy female controls. Patients underwent various surgical
interventions: clitoris reduction and single-stage vagino-
plasty (n = 7), and revaginoplasty (n = 6). In the interviews,
four patients identified themselves as heterosexual. Sexual
milestones had been reached by all patients. Satisfaction with
height, body hair, and external genitalia and sexual fantasies
and interests in the patient group did not diﬀer from the
control group.
A follow-up study by Nordenskjo¨ld et al. [39] on 62
women with CAH aged 18 to 63 years and 62 age-matched
controls to correlate findings of both operative method and
mutations revealed no significant diﬀerences between the
ability of controls and cases to achieve orgasm. Cases were
more likely than controls to be unsatisfied with their vagina
(P = .02), to experience pain during intercourse (P = .004),
to make their sexual debuts later in life (P = .0013), and not
to have children (P = .004).
Schnitzer and Donahoe [40] describe the appropriate
surgical therapy for infants with CAH. The authors rec-
ommend an early one-stage reconstructive surgery, with
the patient’s steroid replacement increased beforehand. The
mainstays of the surgical repair are clitoral recession, correc-
tion of the urogenital sinus defect that results from failure of
the vagina to complete migration to the perineum, and exte-
riorization of the vagina. The authors also recommend that
the labioscrotal folds be trimmed, thinned, and elongated to
create a more normal-appearing labia majora.
Schaeﬀer et al. [27] also recommend surgery according to
the protocols they reviewed.
Recommendation. We recommend performing early, one-
stage feminizing surgery for female infants with CAH.
(Strong recommendation, low-quality evidence).
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(4b) What is the most appropriate feminizing surgery
management of patients with DSD? Surgical management
for children with disorders of sex development is a complex
process that must be individualized with several goals in
mind: preserving normal genital sensation, creating a normal
introitus and providing an adequate vaginal opening at the
perineum. A variety of techniques have been reported in the
literature in the last few decades, but controversy remains
with regard to the timing of performing feminizing geni-
toplasty and neovaginal reconstruction [54–56]. In various
studies, children undergoing feminizing genitoplasty for a
variety of DSD ranged in age from 1 day old to 33 years with
mean follow-up periods of 2 months to 16 years. Stenosis
rates reported in studies addressing delayed vaginoplasty
ranged from 0 to 61.9 percent. Adequate vaginal length was
reported in 60 to 100 percent of cases. Because there are
no randomized controlled trials reported in this population
with regard to specific types of surgical techniques or timing
of reconstruction, data are limited to both small and large
retrospective cohort studies, case series, case reports, and
expert opinion.
Although most studies reported patient satisfaction with
regard to cosmesis, stenosis rates were reported as high as 35
percent. Because of the small numbers within data subsets,
an eﬀect could not be assessed directly with regard to repair
of a high vaginal defect as compared to a low urogenital sinus
defect. Furthermore, the studies reviewed demonstrated too
many inconsistencies to make direct head-to-head study
comparisons.
Only three studies reported on pubertal evaluation
following primary surgery as infants or toddlers. Specific
outcomes with regard to sexual function or sensation were
not available for those who underwent early feminizing
genitoplasty.
The review addressing the appropriate timing and rec-
ommended surgical therapy for children with ambiguous
genitalia consistent with 46, XX DSD or with conditions
resulting in vaginal agenesis yielded 12 retrospective cohorts
(N ranging from 11–178 patients) [57–68], 16 prospective
cohorts (N ranging from 14–200 patients) [69–84] and seven
case series (N ranging from 3–8 patients) [85–91] published
between 1995–2008.
Studies addressing early feminizing genitoplasty for
patients with Prader grade II–V included primary outcome
measures of cosmetic result and stricture or stenosis forma-
tion [57–62, 69–77, 85–88]. Studies in this category reported
mean age at the time of surgical reconstruction as well
as at follow-up periods. Children undergoing feminizing
genitoplasty for a variety of DSDs (CAH, mixed gonadal dys-
genesis [MGD], ambiguous genitalia, androgen insensitivity
syndrome [AIS], ovotestis, true hermaphrodite, intersex,
Mayer Rokitansky Kuster Hauser [MRKH], adrenogenital
syndrome, etc.) ranged in age from 1 day old to 33 years,
with mean follow-up periods of 2 months to 16 years [57–
62, 69–77, 85–88]. Although most studies reported patients’
satisfaction with regard to cosmesis, stenosis rates were
reported as high as 35 percent [69].
Because of the small numbers within data subsets, an
eﬀect could not be assessed directly with regard to repair
of a high vaginal defect as compared to a low urogenital
sinus defect. Furthermore, studies reviewed demonstrated
too many inconsistencies to make direct head-to-head study
comparisons. For instance, six studies reported one surgeon
and one technique [58, 70–73, 85], five studies reported
multiple surgeons ranging from one technique to several
surgical techniques [75–77, 87, 88], and seven studies did not
specifically list number of surgeons or techniques involved
[57, 59–62, 74, 85, 86]. Only three studies reported on
pubertal evaluation following primary surgery as infants or
toddlers [71, 75, 86].
Specific outcomes with regard to sexual function or
sensation were not available for those who underwent early
feminizing genitoplasty. For delayed vaginoplasty, 16 studies
reporting on eight diﬀerent techniques (Dilator therapy,
McIndoe, Davydov, Vecchietti, Sigmoid, Amnion, Creatsas,
Williams) between 1997, and 2010 were assessed [63–68, 78–
84, 89–91]. Reasons for performing vaginoplasty included
MRKH, CAH, AIS, MGD, cloaca, vaginal agenesis, and
true hermaphrodite. Patients’ ages ranged from 7 to 26
years old at the time they underwent isolated vaginoplasty.
Thirteen studies included only pubertal or postpubertal
patients [63, 66, 67, 78–84, 89–91] whereas three studies
included prepubertal females [64, 65, 68]. Follow-up periods
varied from 3 to 111 months. Stenosis rates reported in
studies addressing delayed vaginoplasty ranged from 0 to
61.9 percent [63–68, 78–84, 89–91]. Adequate vaginal length
was reported in 60 to 100 percent of cases. Unwanted vaginal
discharge was assessed in four studies utilizing bowel for
neovaginal reconstruction, ranging from 4.3 to 100 percent
[63–68, 78–84, 89–91].
Several consensus documents addressed disorders of
sexual diﬀerentiation [54–56]. A clear trend throughout
all existing recommendations is toward multidisciplinary
management. Pediatric surgeons, urologists, and gynecolo-
gists advocate that cases of DSD should be individualized
and no gender assignment should be made without proper
evaluation. Surgical correction is delayed until a definitive
diagnosis has been established. However, once established,
the rationale for early surgical correction includes beneficial
eﬀects of estrogen in the initial 6 months postdelivery
for wound healing and limiting postoperative stricture
formation, minimizing family distress related to anatomic
concerns, andmitigating the risks of stigmatization or gender
identity confusion. Despite the best intentions, adverse
outcomes also have led to recommendations from some
organizations to delay surgery until an appropriate age of
informed consent [54, 57, 58, 70]. Other surgeons still have
advocated for staging feminizing genitoplasty based on the
location of the vaginal confluence, though no prospective
studies have specifically evaluated the many techniques for
urogenital sinus repair.
Most surgeons agree that vaginoplasty cases may be more
appropriately delayed among those requiring more complex
reconstruction or at high risk for stricture formation [57, 58,
60, 70]. If decisions are made to perform clitororeduction,
modern surgical trends are toward conservation of neurovas-
cular and/or erectile structures, although long-term satisfac-
tion and sexual function are unknown [54, 56, 70, 85, 87].
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Finally, all consensus opinions recommend full informed
consent prior to initiating the reconstruction process, with
the caveat that certain cases may require staged procedures
and/or revision in adolescence or adulthood [54–56].
Recommendation. We recommend that cases be individual-
ized due to the spectrum in presentation, and that surgery
should be delayed until a definitive gender assignment
can be established. (Strong recommendation, low-quality
evidence).
(4c) What is the most appropriate masculinizing surgery
management of patients with DSD? Our review of the
literature revealed scant and low-quality data to support a
single, unified surgical approach to patients with 46, XY.
Techniques described for surgical reconstruction of the
patient with an undermasculinized perineum and male
gender assignment include staged versus primary hypospa-
dias repair, scrotoplasty, orchidopexy, open or laparoscopic
removal of mu¨llerian structures, and insertion of prostheses.
Controversy continues regarding the appropriate surgical
technique(s) and the timing of surgical intervention, as no
randomized controlled trials have been performed on this
patient population. Our results yielded a variety of outcomes.
The 57 patients in the series by Chertin, et al. [41] who
underwent various masculinizing genitoplasty techniques,
according to the quality of the urethral plate, were evaluated
at 6-year follow-up: 7 percent of children had breakdown
of the urethroplasty and required redo surgery, 12.8 percent
developed a urethral fistula requiring closure, and 59 percent
achieved satisfactory cosmetic and functional results per
parental and surgeon assessment.
The series of 85 children reported by Go¨llu¨ et al. [42]
had results that were contrary to other studies evaluating
the outcomes of staged hypospadias repair, with a 34 percent
complication and re-do operation rate.
Lam et al. [43] reported that of the 44 boys in their study
who underwent staged repair, the complications rates were
6.8 percent for fistula formation and 23 percent for stricture.
The minor complication rates reported were expected given
the long neourethras created in the procedures they under-
went. Mild pain with erection was reported by 8 percent; 92
percent were pleased with their physical appearance.
The retrospective study by Nihoul-Fe´ke´te´ et al. [44] of
patients undergoing early corrective surgery for 46, XY DSD
and ovotesticular DSD had a negative correlation between
the number of basal procedures required and the year of
birth, likely due to the adoption of one-stage procedures
after 1980. Fourteen-year follow-up revealed that anatomical
results were worse for idiopathic 46, XY DSD (n = 9),
with three patients needing multiple surgical interventions
and developing fistulas; one patient had an untreatable
penile deformity. These authors also report that poor brain
masculinization occurs in androgen receptor deficiency,
explaining why sex reversal is rare in partial androgen
insensitivity. In their series, patients with partial androgen
insensitivity reared as males had very poor self-reported
satisfaction after surgical treatment (range 3–11 operations)
due mainly to buried penis and micropenis. Only one of
four patients with deficiency caused by 5 alpha-reductase
underwent the typical male gender transition that follows
virilization during puberty. All four others requested female
genitoplasty and appear to be well adjusted.
In the long-term follow-up study by Farkas and Rosler
[45] of 16 patients who underwent masculinizing genito-
plasty for 17-hydroxysteroid dehydrogenase deficiency, in
which a staged approach was used in most patients, com-
plications included complete breakdown of the neourethra
requiring re-do surgery in one patient, and three small
fistulae, and development of distal meatal stenosis and
orchidoepididymitis in one patient who underwent single-
stage reconstruction. Overall, the authors conclude that
combination of testosterone and staged surgery resulted in
pleasing appearance of external genitalia inmost patients and
recommended MGP for androgen-responsive patients with
17-hydrogenase deficiency.
Mendonca et al. [46] reported a cohort of 46, XY patients
with 5 alpha-reductase deficiency in Brazil; 14 of 25 patients
registered as the female social sex changed to a male gender
role around the time of puberty. Thirteen of these patients,
after psychological evaluation, underwent 2- or 3-stage
surgery consisting of orthophalloplasty, scrotoplasty with
resection of vaginal pouch, urethroplasty, and orchidopexy
when necessary. The most frequent complications were
urethral fistula (n = 6) and scrotal abscess (n = 2);
one patient had bilateral epididymitis with transient penile
and scrotal edema. Psychological evaluation of 25 patients
reared as females revealed male identity in 13 of them.
Subjects treated at a later age described social inadequacy,
psychological anguish, and suicidal ideas, and all would
have preferred to have been treated in childhood. Patients
who changed to male sex appeared to have a better social
adjustment than did those who kept female social sex. Thus,
the authors conclude that their findings support the theory
that in utero or postnatal exposure to testosterone leads to
imprinting of male sexual identity.
Lima et al. [47] reported that the sixmale patients in their
study who underwent laparoscopic removal of Mu¨llerian
duct remnants had no complications, resumed oral intake
by postoperative day one, and were discharged by day 5
after their catheters were removed. All patients remained
free from urogenital tract infections, voiding dysfunctions or
urinary incontinence at a follow-up range of 6 months to 4
years. The authors conclude that when compared with other
surgical approaches, the laparoscopic approach provides
minimally invasive access to the retrovesical space with
excellent exposure, decreasing the incidence of complications
and operative time and avoiding large scars.
With regard to the appropriate timing of surgical
intervention for patients with ovotesticular DSD and an
underandrogenized perineum, no conclusive high-quality
evidence was found. Most manuscripts reviewed point to
early surgical intervention once male sex assignment is made
in an eﬀort to minimize parental anxiety and the long-term
psychological eﬀects on the patient.
Recommendation. We recommend postponing surgical
management until concordance can be established.
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For underandrogenized male patients and underlying
testosterone deficiency, particularly 17-beta hydroxysteroid
dehydrogenase deficiency, and incomplete androgen insensi-
tivity, we recommend preoperative testosterone stimulation
to confirm penile response to androgens and increase in
phallus size, followed by masculinizing genitoplasty and
orchidopexy. For underandrogenized male patients with 5
alpha-reductase deficiency, we recommend pre-operative
testosterone stimulation followed by hypospadias repair and
scrotoplasty, as well as dihydrotestosterone replacement.
(Strong recommendation, low-quality evidence).
(4d) What is the most appropriate gonadectomy surgery man-
agement of patients with DSD? The study by Olsen et al. [48]
of a 15-month-old phenotypic female who was diagnosed
as having 46,XY gonadal dysgenesis following karyotyping
for Turner-like features resulted in gonadectomy at the time
of bilateral ureteral reimplantation for vesicoureteral reflux
showed gonadoblastoma; malignancy was established at 15
months.
In the case study by Dumic et al. [49], a 9-month-
old infant with hypertrophic clitoris and separated ure-
thral and vaginal opening was diagnosed as having 46,XY
incomplete “pure gonadal dysgenesis.” Examination of both
gonads revealed gonadoblastoma and bilateral salpingo-
gonadectomy; partial hysterectomy was performed.
Fallat and Donahoe [50] note that the gonads most at
risk for malignant transformation are both dysgenetic and
intraabdominal and that early gonadectomies are recom-
mended, as malignancies have been reported in infancy. Pre-
dominant risk groups include syndromes of gonadal dysge-
nesis and Ullrich-Turner syndrome. Partial gonadectomy is
feasible in individuals with ovotesticular DSD commensurate
with sex of rearing. Histologically normal intraabdominal
gonads may be left through puberty (androgen insensitivity
syndromes) [31]. A palpably normal descended gonad in a
child with a Y chromosome can be observed if the child
is reared as male. Certain intersex syndromes with splice
variants of the WT1 gene are susceptible to Wilms’ tumors
(Frasier and Denys-Drash syndromes).
Recommendation. We recommend early gonadectomy in
cases of gonadal dysgenesis. However, in cases of CAIS,
gonadectomy is delayed until after puberty. (Strong recom-
mendation, very low-quality evidence.)
5. Remarks
These recommendations place a high value on patient- and
family-centered care and interdisciplinary communication.
Despite the lack of controlled data for infrastructure support
and care delivery, we provide strong recommendations, in
part because there is clear data in general care delivery that
inconsistent communication and coordination lead to poor
outcomes.
6. Consensus Statement
In addition to the studies described herein and that
form our evidence-based conclusions, we have taken into
consideration the consensus statement on management of
intersex disorders by the International Consensus Con-
ference on Intersex [55]. It has been reviewed and the
classifications of the DSD have been taken into account by
our team.
Based on the evidence described in the papers described
herein, the GMT task force consensus statement includes
recommendations for (1) laboratory workup, (2) immediate
acute management, (3) sex assignment in an ethical frame-
work that includes education and involvement of the parents,
and (4) surgical management. The GMT task Force makes
the following recommendations for clinical practice.
(1) Laboratory Workup.
(i) Standard workup for CAH: electrolytes, glucose,
17OHP, plasma renin, D4 androstenedione, testos-
terone, 11deoxycortisol, DHEA.
(ii) Standard workup for hypopituitarism/ hypogo-
nadotropic hypogonadism: testosterone, LH, FSH,
glucose, T4 (free thyroxine by equilibrium dialysis),
TSH, testosterone, LH, FSH [14], and random corti-
sol versus 1mcg ACTH.
(iii) Workup for micropenis, undescended testes in the
context of primary hypogonadism or in the context of
first valuation of action or production of testosterone
biochemical levels: testosterone baseline, stimulation
with HCG as referenced by Davenport [17] (500 units
q day × 3 days for younger than 1 year of age), and
draw testosterone, dihydrotestosterone on day 4.
(iv) Genetic testing as appropriate for ambiguous geni-
talia depending on karyotype and phenotype [15],
which includes molecular genetics as needed for 5
alpha-reductase and androgen receptor defects.
(2) Immediate Acute Management.
(i) For CAH and hypopituitarism, management is
directed toward the emergency condition.
(ii) For suspected CAH (salt-losing variety), an appro-
priate laboratory workup is done, and the infant
is treated with D5 NS (dextrose in normal saline)
and stress steroids (100mg/m 2/day), with treatment
modified after 24 hours, based on electrolyte correc-
tion; Florinef (0.1mg po qd) is added, with a switch
to table salt (2.5 grams po qd/given in 24-hr worth of
formula).
(iii) For micropenis and suspicion of hypopituitarism
(the concern is hypoglycemia), the pituitary adrenal
axis is assessed for cortisol production and treatment
(stress steroids: 100mg/m 2/day Solucortef) is initi-
ated while laboratory results are pending. If neither of
the acute conditions is the final diagnosis, treatment
is withdrawn after the results of the workup are
available.
(3) Sex Assignment. The GMT task force recommends that
physicians implement an educational component within an
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Table 1: DSD examples and sex assignment considerations.
Condition Sex assignment Evidence Grade
CAH Usually female Berenbaum and Bailey [92]
Strong recommendation with very low quality
Evidence for female sex assignment.
CAIS Female Wisniewski et al. [93]
Strong recommendation with very low quality
evidence for female sex assignment.
PAIS Depends on the phenotype Ko¨hler et al. [94]
Consensus statement to base sex assignment on
the phenotype.
Gonadal dysgenesis Usually female Sarafoglou and Ostrer [95]
Consensus statement for female sex assignment in
most instances.
Hypospadias Usually male Boisen et al. [96]
Weak recommendation with low quality evidence





Consensus statement for male sex assignment,
and to evaluate babies within the first 6 months
and treat with testosterone.
Ovotesticular syndrome Depends on the continent Hadjiathanasiou et al. [97]
Strong recommendation with very low quality
evidence. assign gender on an individual basis.
5α-Reductase deficiency Depends on the continent
Imperato-McGinley et al.
[21]
Strong recommendation with very low quality
evidence. assign gender on an individual basis
with appropriate consideration of the patient’s
degree of masculinization.
ethical framework that includes the parents in the decision-
making process. That framework is based upon the following
interactions: practice is based on the composite of factors
listed below, which serves as an educational tool for the
parents and provides a platform for generating the consensus
among the stakeholders [28].
(i) The Gender Medicine Team discusses implications of
establishing the child’s sex assignment with the help
and participation of the ethicist, presents the results
and workup to the parents, and establishes the long-
term setting for follow-up.
(ii) Education is provided to the parents for the sex
assignment process before a decision is reached. The
parents are active participants in the process and are
presented diﬀerent components of sex assignment as
well the diﬀerent alternatives (Table 1).
(iii) The GMT task force recommends postponing sex
assignment until (1) the entire GMT, including the
ethicist, has fully assessed the child’s condition and
the situation, and (2) the parents have received
adequate education and counseling, if necessary, to
participate in making the decision concerning their
child’s sex assignment.
The evaluation that the GMT follows is one of standard
practice, which begins with determination of whether the
type of DSD the patient has is one condition or if there
is multiple-organ involvement. Evaluation of the external
genitalia is followed, as needed, by ultrasound evaluation
of the internal genitalia. Clinical testing to establish chro-
mosomal and molecular sex is performed, as are studies to
determine the gonadal sex and endocrine studies. The patient
also is supported by psychological counseling. The precise
algorithm used is shown in Figure 1.Precedence for this type
of approach is exemplified by the gender assessment team
described in Parisi et al. [15].
7. Conclusions
The medical practice of sex assignment for individuals
with DSD defies the conventional path of any established
decision-making process and opens an opportunity for the
medical field to define a consensus practice for the diﬀerent
subspecialties involved in a GenderMedicine Team. Based on
our experience in this field, we suggest that both the parents
and an ethicist who can ensure that the sex-assignment
decision is within an ethical framework for treating persons
with DSD be included as participants in the consensus [28,
33, 34].
Guidelines are essential in our practice and, despite
the paucity of systematic outcomes and prospective studies
in the field of gender medicine, the workup and medical
management of the infant born with ambiguous genitalia
is now the standard of care. However, once the diagnostic
workup and any necessary acute interventions have been
completed, the practices for making sex assignments vary
from center to center.
Accordingly, the team that we assembled at Texas Chil-
dren’s Hospital decided to operate on a consensus basis, using
the multidisciplinary team’s expertise and incorporating the
work of the pioneers in the field. One such example is Maria
New, who advocated prenatal diagnosis and treatment of
CAH babies in utero to avoid virilization of the external
genitalia [98].
The virilization of genitalia that occurs in infants
with CAH 21-OHlase deficiency can be corrected during
intrauterine life, establishing that sex assignment does not
rely by any means on the phenotype of the external genitalia.
Other pioneers in the field include Mel Grumbach, Charles
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Sulton, Phyllis Speiser, and Perrin White, who established
the management of ambiguous genitalia [11, 12, 14] by
expanding our understanding of the biology of conditions of
DSD and by demonstrating how early hormonal abnormali-
ties can aﬀect the fetus (aromatization) [99]. More recently,
Roger Gorski, one of the original pioneers in studying the
sexual dimorphism of the brain, demonstrated that not
only the external genitalia but also the brain is a sexually
dimorphic organ and a target of the hormones [100]. In
addition, Sherry Berenbaum [92] evaluated girls with CAH
and found some variability in their play behavior as a
consequence of the hormonal influences.
Using the wisdom we inherited from the pioneers in
gendermedicine, we established and implemented guidelines
that include the participation of the parents within an ethical
framework provided by our ethicist. We suggest a simple
algorithm for the workup, follow the uniform practices of
most centers as standard of care, establish the diagnosis,
and, unless a medical emergency exists, delay surgery until
education of the parents is completed. We will continue
to incorporate the long-standing evidence in the field and
to establish methodology by evaluating and grading our
practice in this field. We target our management for gender
stability by providing support through our psychologist in
the event of a sex change, should that be the choice of the
individual; this matter can be addressed as part of the course.
There are, of course, certain financial implications with our
model, and only time and new directions in health care will
prove whether ours is an eﬃcient model.
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